Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Johnson & Johnson (JNJ) is a leading drug manufacturers-general business based in the US. It opened the day at $164.51 after a previous close of $163.93. During the day the price has varied from a low of $164.21 to a high of $165.77. The latest price was $164.82 (25 minute delay). Johnson-and-Johnson is listed on the NYSE and employs 136,000 staff. All prices are listed in US Dollars.
|52-week range||$130.31 - $178.93|
|50-day moving average||$173.17|
|200-day moving average||$167.11|
|Wall St. target price||$188.88|
|Dividend yield||$4.09 (2.48%)|
|Earnings per share (TTM)||$6.65|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-16)||-0.24%|
|1 month (2021-08-24)||-6.03%|
|3 months (2021-06-24)||0.89%|
|6 months (2021-03-24)||1.80%|
|1 year (2020-09-24)||13.93%|
|2 years (2019-09-24)||25.29%|
|3 years (2018-09-24)||17.33%|
|5 years (2016-09-23)||38.73%|
Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson-and-Johnson shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6794. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30.7 billion.
The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$89.2 billion|
|Operating margin TTM||25.98%|
|Gross profit TTM||$54.3 billion|
|Return on assets TTM||8.65%|
|Return on equity TTM||26.81%|
|Market capitalisation||$432 billion|
TTM: trailing 12 months
There are currently 16.4 million Johnson-and-Johnson shares held short by investors – that's known as Johnson-and-Johnson's "short interest". This figure is 4.8% down from 17.2 million last month.
There are a few different ways that this level of interest in shorting Johnson-and-Johnson shares can be evaluated.
Johnson-and-Johnson's "short interest ratio" (SIR) is the quantity of Johnson-and-Johnson shares currently shorted divided by the average quantity of Johnson-and-Johnson shares traded daily (recently around 5.2 million). Johnson-and-Johnson's SIR currently stands at 3.14. In other words for every 100,000 Johnson-and-Johnson shares traded daily on the market, roughly 3140 shares are currently held short.
However Johnson-and-Johnson's short interest can also be evaluated against the total number of Johnson-and-Johnson shares, or, against the total number of tradable Johnson-and-Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson-and-Johnson's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Johnson-and-Johnson shares in existence, roughly 10 shares are currently held short) or 0.0062% of the tradable shares (for every 100,000 tradable Johnson-and-Johnson shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson-and-Johnson.
Find out more about how you can short Johnson-and-Johnson stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson-and-Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson-and-Johnson's overall score of 35.8 (as at 12/31/2018) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson-and-Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.79/100
Johnson-and-Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 25.14/100
Johnson-and-Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.87/100
Johnson-and-Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson-and-Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson-and-Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson-and-Johnson has a damaged public profile.
|Total ESG score||35.8|
|Total ESG percentile||72.38|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||4|
Dividend payout ratio: 45.35% of net profits
Recently Johnson-and-Johnson has paid out, on average, around 45.35% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.57% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 2.57% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.09 per share.
While Johnson-and-Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson-and-Johnson may be investing much of the rest of its net profits in future growth.
Johnson-and-Johnson's most recent dividend payout was on 6 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 22 August 2021 (the "ex-dividend date").
Johnson-and-Johnson's shares were split on a 2:1 basis on 12 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson-and-Johnson shares which in turn could have impacted Johnson-and-Johnson's share price.
Over the last 12 months, Johnson-and-Johnson's shares have ranged in value from as little as $130.313 up to $178.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.7047. This would suggest that Johnson-and-Johnson's shares are less volatile than average (for this exchange).
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o. b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.